Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025

Domain Therapeutics France Canada United States of America

Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of  recommended Phase II dose (RP2D) for further development in solid tumorsPreclinical data of DT-7012 position this Treg depleting anti-CCR8 antibody as a highly differentiated candidate for clinical development Preclinical findings demonstrate high potential of the PAR2 biased negative allosteric modulator (NAM) program to potentiate anti-tumor immunityView original content:https://www.prnewswire.co.uk/news-releases/domain-therapeutics-presents-novel-data-addressing-key-challenges-in-oncology-at-aacr-2025-302441519.html